Safety
deaths, nausea, neutropenia, fatigue, leukopenia, fever, proteinuria, anemia, hypothyroidism, alopecia, anorexia
ADVERSE EVENT, NEUTROPENIA, LEUKOPENIA, ADVERSE EVENTS, ANEMIA, ADVERSE EVENT, HYPOTHYROIDISM, ALOPECIA, ANOREXIA
The most common adverse events were leukopenia (56.7%), anemia (56.7%), neutropenia (56.7%), alopecia (53.3%), fatigue (46.7%), elevated AST (40.0%), anorexia (36.7%), elevated ALT (36.7%), hypothyroidism (36.7%), proteinuria (36.7%) and nausea (30.0%). However, most of these adverse events were grade 1 or 2. The most common grade 3 or 4 treatment-related adverse event was neutropenia (13.3%), followed by leukopenia (6.7%). Two patients developed grade ≥ 3 neutropenia with fever and recovered after supportive treatment. One patient developed grade 3 anemia and recovered after a blood transfusion. One patient developed grade 3 hepatic transaminase elevation, including ALT, AST, alkaline phosphatase, and gamma-glutamyl transpeptidase. This was considered as an immune-related adverse event and was resolved by glucocorticoid treatment. One patient developed grade 3 bilirubin elevation, which resolved after treatment with a glucocorticoid combined with mycophenolate mofetil, considering immune-related factors. No treatment-related deaths occurred. Details of adverse events are shown in Table 
Treatment-Related Adverse Events